HomeNewsBusinessMarketsSebi bars API maker Par Drugs from slump sale, orders independent valuation and fairness opinion

Sebi bars API maker Par Drugs from slump sale, orders independent valuation and fairness opinion

The Sebi investigation follows a complaint alleging that PDCL’s slump sale is being executed at an artificially low valuation to benefit promoter-related entities at the expense of public shareholders.

September 15, 2025 / 19:10 IST
Story continues below Advertisement
Sebi Bars Par Drugs from Proceeding with Slump Sale, Orders Independent Valuation and Fairness Opinion
Sebi Bars Par Drugs from Proceeding with Slump Sale, Orders Independent Valuation and Fairness Opinion
Moneycontrol News
first published: Sep 15, 2025 07:09 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!